Tranexamic acid (TXA) is a versatile antifibrinolytic agent, but determining the optimal dose and administration strategy can be complex, as effectiveness and safety can vary significantly depending on the clinical indication, patient factors, and route of administration.

In acute bleeding situations like trauma and postpartum hemorrhage (PPH), prompt administration is key. For trauma, early administration (within 1-3 hours of injury) is associated with the greatest mortality benefit, typically involving a 1-gram loading dose followed by an infusion. In PPH, immediate administration of 1 gram intravenously is recommended, with a second dose if needed.

For surgical procedures, dosage strategies differ. In cardiac surgery, where higher doses have been used, there's a trend towards lower doses (e.g., 10-15 mg/kg) to mitigate seizure risk, while still achieving hemostatic benefits. Orthopedic surgeries often utilize doses around 10-20 mg/kg, with combined intravenous and topical applications showing enhanced efficacy.

The route of administration also plays a role. While intravenous administration provides rapid systemic effects, topical application can minimize systemic absorption and reduce the risk of systemic side effects, making it a viable option for patients at high risk for thrombotic events or in specific surgical sites.

Factors such as renal function necessitate dose adjustments, as impaired kidney function can lead to TXA accumulation. Furthermore, the 'dose makes the poison' principle applies; higher doses may increase efficacy for bleeding control but also elevate the risk of adverse events like seizures.

Choosing the right tranexamic acid dosage requires careful consideration of the patient's condition, the specific bleeding scenario, and potential risks. While guidelines provide a framework, individualized treatment strategies, potentially guided by viscoelastic coagulation assays, are essential for optimizing outcomes and ensuring patient safety.